Damora Therapeutics, Inc. (DMRA) SEC Filings & Earnings Calls

No revenue, pre-commercial stage

“The Company has incurred recurring losses and has not generated revenue as no products have obtained the necessary regulatory approval in order to market products.” · word for word

Dependence on Paragon/Paramora relationship

“The Company is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with mark-up costs pursuant to the terms of the Paragon Option Agreement.” · word for word

Significant dilution from equity offerings

“Common shares outstanding increased from 1,597,321 at Dec 31, 2025 to 61,734,601 at June 30, 2026.”

Change in governing law from Delaware to Cayman Islands may alter shareholder protections and rights.

“Internal affairs of the Company ceased to be governed by Delaware law and instead are governed by Cayman Islands law.” · word for word

New CUSIP number may cause temporary trading confusion.

“Company ordinary shares were represented by a new CUSIP number (G2646Y104).” · word for word

Pre-revenue biotech with no approved products

“The Company has incurred recurring losses and has not generated revenue as no products have obtained the necessary regulatory approval in order to market products.” · word for word

Dependence on additional financing

“The Company will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold.” · word for word

CFO departure may indicate internal challenges; accelerated equity vesting suggests negotiated separation.

“all of Ms. Firmani’s outstanding equity awards will be fully accelerated.” · word for word

Going Concern Risk (Historical)

“such report for the fiscal year ended December 31, 2024 contained an explanatory paragraph related to the Company’s ability to continue as a going concern.” · word for word

Management Turnover

“Dr. Schambye ceased serving as the Company’s Chief Executive Officer and President, and his employment was terminated by the Company without cause, effective as of February 10, 2026.” · word for word

Auditor Change

“the Audit Committee dismissed EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm, effective as of April 17, 2026. ... The Audit Committee engaged Ernst & Young LLP as the Company’s independent registered public accounting firm, effective as of April 17, 2026.” · word for word

Going concern qualification in prior audit report indicates material uncertainty about ability to continue as a going concern.

“report for the fiscal year ended December 31, 2024 contained an explanatory paragraph related to the Company’s ability to continue as a going concern” · word for word

Leadership transition risk; three directors resigned simultaneously

“Amit Munshi, Carl Goldfischer and Jayson Dallas resigned from the Board effective March 23, 2026” · word for word

Preclinical stage, no revenue, high cash burn

“We have no products that have been dosed in humans or approved for commercial sale, have not generated any revenue from product sales to date, and continue to incur significant research and development and other expenses related to our ongoing operations.” · word for word

Dependence on single product candidate DMR-001

“Our future success is substantially dependent on our ability to timely obtain regulatory approval for, and then successfully commercialize, DMR-001.” · word for word

Need for additional capital; going concern risk

“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.” · word for word

Pre-revenue biotech with clinical-stage pipeline; regulatory and clinical trial risks.

“Pipeline in early clinical development; no approved products.”

Company may use capital sooner than anticipated.

“The Company could use its available capital resources sooner than it currently anticipates.” · word for word

Leadership vacuum and potential strategic drift

“CEO departure without permanent successor; interim COO appointed”

Forward-looking statements; clinical and regulatory risks.

“Forward-Looking Statements” · word for word

Potential dilution from warrant exercise and equity grants to new COO.

“Warrant for 628,302 shares and RSU/option grants to new COO.”

Redomestication to Cayman Islands may reduce shareholder protections

“The Cayman Islands has a different body of securities laws as compared to the United States and provides less protection to investors.” · word for word

Potential dilution from new equity plans

“The initial share pool under the 2026 Equity Plan will be 9,299,832 shares of Common Stock... automatically increased on January 1 of each year... in an amount equal to 5% of the diluted stock.” · word for word

Significant dilution to existing Galecto shareholders due to issuance of convertible preferred shares (each convertible into 1,000 common shares).

“each share of which is convertible into 1,000 shares of Common Stock” · word for word

Damora is a clinical-stage biotech with no approved products; pipeline risk is high.

“Damora is developing DMR-001 for myeloproliferative neoplasms, still in Phase 1 clinical proof-of-concept stage.”

Going concern risk

“These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date our financial statements are issued.” · word for word

Cash runway limited

“we believe that our existing cash and cash equivalents of $7.6 million as of September 30, 2025 will be sufficient to fund the preclinical development of GB3226 into 2026, including the submission of an IND to the FDA.” · word for word

Dependence on additional financing

“We will require substantial additional capital to finance our operations, including clinical development of any of our GB3226 and GB1211 programs.” · word for word